Determining When to Add Nonstatin Therapy A Quantitative Approach

ConclusionsAdding ezetimibe or PCSK9 monoclonal antibodies to maximally tolerated statin therapy may  be cost effective in very high-risk and high-risk patients, depending on baseline LDL-C levels.
Source: Journal of the American College of Cardiology - Category: Cardiology Source Type: research